- Home
- ADEA vs VKTX Comparison
ADEA vs VKTX Comparison
Compare ADEA & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADEA | VKTX |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADEA | VKTX |
|---|---|---|
| Price | $29.25 | $37.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.00 | ★ $95.86 |
| AVG Volume (30 Days) | 2.2M | ★ 2.8M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.63 | N/A |
| P/E Ratio | $146.00 | ★ N/A |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $11.61 | $22.96 |
| 52 Week High | $34.34 | $43.15 |
Technical Indicators
Market Signals| Indicator | ADEA | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 65.52 |
| Support Level | $28.93 | $32.66 |
| Resistance Level | $33.98 | $39.78 |
| Average True Range (ATR) | 1.99 | 2.16 |
| MACD | -0.15 | 0.75 |
| Stochastic Oscillator | 19.24 | 69.33 |
Price Performance
Historical ComparisonAbout ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.